OncoRes Medical receives $150,000 funding boost from Western Australian Government
With health policy top of the political agenda, now’s the time to supercharge Australia’s biotech sector says new MRCF Board member
Erica Kneipp tapped for $700m biotech fund
Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals
Nasal spray which could fight Covid and other respiratory infections gets funding
New investments for drug research
Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
OncoRes Medical wins IGNITE Madness 2020
Eyeing pandemic’s silver lining for drug trials
Azura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease
Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
Nasal spray cuts COVID-19 growth, study shows
Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions
GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)
OncoRes Medical awarded prestigious research funding
Innovative type two diabetes treatment scores $29m
$29M investment to develop new treatment for type 2 diabetes
Vaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate
Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)
Nation faces ‘generational loss’ of biotechs warning
Urgent COVID-19 response package needed to support and protect $170b life sciences sector
Bill Ferris, pioneer venture capitalist, appointed Chair of the MRCF
Vaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin
Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination
Multi-million-dollar mission to tackle major global health challenges
MRCF establishes life science incubator to boost NZ startup successes
QUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats
$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease
FDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System
Perth tech joint-winner in global finals for international start-up competition
EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO
Q-Sera’s innovative blood clotting technology granted patent in US
QUE Oncology launches Phase II trials in New Zealand
QUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors
PolyActiva completes recruitment in key Phase I glaucoma implant safety study.
Morphoseq™ at ‘Sequencing, Finishing and Analysis in the Future’ meeting, USA
Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology
Brandon Capital Partners launches new Medical Research Commercialisation Fund, seeks NZ institutional
QUE Oncology launches Phase II trials in the United States
MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis
Aravax reveals positive Phase I trial results at world-leading allergy conference
Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis
Perth tech takes out Australian start-up competition to join international finals
The WILD Program launches within the Victorian STEM sector, with first intake of 20 women
QUE Oncology launches Phase II trials
PolyActiva commences first Phase I clinical trial with potential to improve lives of millions
Paragen Bio launches in northern Queensland with $6 million investment
MRCF announces largest investment to date by Biotechnology Translation Fund
MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia
Australian biotech company launched with AU$7m investment to develop therapies for treating obesity
Auspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections
New Zealand biomedical discovery set to revolutionise the global pain relief drug market
Q-Sera’s innovative blood clotting technology patent granted in China
Australian investors lead AU$60m raise to develop new technology
Osprey Medical and AKI highlighted at largest international cardiovascular conference TCT 2017
Q-Sera’s ground-breaking blood clotting technology presented at leading scientific conference in South Africa
